![肿瘤药物治疗方案及综合评价](https://wfqqreader-1252317822.image.myqcloud.com/cover/13/43604013/b_43604013.jpg)
上QQ阅读APP看本书,新人免费读10天
设备和账号都新为新人
HER-2阳性晚期胃癌的治疗
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T211_228_2045_1988_2807_148586.jpg?sign=1738891663-rmC4YsMbdGTFgkNDFmedO0566tS6aDIO-0-dfef521c9cae106cb134f015573d1b0f)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T212_285_341_2023_2836_148588.jpg?sign=1738891663-ii49NdTBGCFgjo51jW5Ux4s5MJOWO9lJ-0-67704a136ffcb297564308b9434475c3)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T213_238_343_1948_730_146943.jpg?sign=1738891663-8532DnFNcFHfelc1iVQ5SnwtvnRMGlN4-0-e162768f2bf7728cae03ec635aa7a86d)
点评
曲妥珠单抗联合XP方案化疗为HER-2阳性的晚期胃及胃食管结合部腺癌患者的一线首选治疗方案。该研究证据源于ToGA研究(NCT01041404),为一项国际多中心Ⅲ期随机对照试验,旨在比较曲妥珠单抗联合化疗在HER-2阳性胃癌、胃食管癌中的有效性,结果发现:曲妥珠单抗联合化疗延长了HER2阳性患者的OS、PFS,本研究首次在大样本胃癌临床研究中使晚期胃癌患者生存期超过13个月,并在个体化治疗层面开启了胃癌靶向治疗的新篇章。
(张 涛 于丹丹)
参考文献
[1] BANG YJ,VAN CUTSEM E,FEYEREISLOVA A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(TOGA):a phase 3,open-label,randomised controlled trial(vol 376,pg 687,2010).Lancet,2010,376:1302-1302.